Parkinson’s disease
A slowly progressive neurologic disease that is characterized by a fixed inexpressive face, tremor at rest, slowing of voluntary movements, gait with short accelerating steps, peculiar posture and muscle weakness (caused by degeneration of an area of the brain called the basal ganglia), and low production of the neurotransmitter dopamine. Most patients are over 50, but at least 10 percent are under 40. Treatment involves use of medication, such as levodopa (brand name: Larodopa) and carbidopa (brand name: Sinemet).
- Pneumonia
- Multiple Systems Atrophy
- Progressive Supranuclear Palsy
- Normal Pressure Hydrocephalus
Related Conference of Parkinson’s disease
June 22-23, 2026
18th Global Neurologists Meeting on Neurology and Neurosurgery
Amsterdam, Netherlands
June 29-30, 2026
31st International Conference on Neurology: Neurochemistry, Neuropharmacology and Neurosciences
Paris, France
July 20-21, 2026
11th International Conference on Central Nervous System Disorders & Therapeutics
Amsterdam, Netherlands
July 23-24, 2026
14th International Conference on Cannabis & Medicinal Research
Amsterdam, Netherlands
September 17-18, 2026
31st Global Experts Meeting on Neuroscience and Neuropharmacology
Paris, France
April 27-28, 2027
18th International Conference on Stroke, Neurology and Cerebrovascular Diseases
Paris, France